Raia Drogasil Sales Surge 18.3% But Profit Lags at 7.4%

Brazil · Health

Brazil’s largest pharmacy chain posts strong revenue growth in the second quarter, though rising costs squeeze margins and slow profit gains.

Raia Drogasil posted another quarter of blockbuster sales growth, but investors are watching one thing: profits are not keeping pace. Brazil’s largest pharmacy chain lifted gross revenue 18.3% to R$12.778 billion (US$2.5 billion) in the second quarter of 2026. Adjusted net profit climbed just 7.4% to R$432.7 million (US$84.7 million).

Raia Drogasil operates over 3,000 drugstores across Brazil, with digital sales now a key growth driver. (Photo: Internet Reproduction)

Why Sales Growth Accelerated at Raia Drogasil

Revenue growth picked up speed, from 13.9% in 2025 to 18.3% this quarter. The push came from new store openings and a 55% jump in digital sales, as the company noted in its earnings release.

The chain added dozens of new drugstores across Brazil during the quarter. Management also leaned into its online sales push, which now makes up a growing slice of total revenue.

With over 3,000 stores nationwide, the company is expanding into smaller cities where demand for health products is rising. This geographic reach helps steady revenue even when the economy wobbles.

What Raia Drogasil does. Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.

Why Profit Growth Lagged Behind

Profit growth slowed to single digits, even as revenue boomed. Analysts at Eu Quero Investir said higher operating costs and spending on logistics expansion are eating into what is left at the bottom line.

Rising wages and freight charges also added pressure. The company is investing heavily in new warehouses and delivery networks, which costs money today but should pay off later.

core earnings Holds Steady

Core operating earnings reached R$1.017 billion (US$199.1 million), up 17.9% year over year. The core operating earnings margin stayed flat at 8.0%, according to Reuters via InfoMoney.

That steady margin shows management is keeping costs in check despite inflationary pressures. But the slower net income growth suggests interest expenses and taxes are weighing more heavily.

Digital Push Drives Gains

Digital sales were the standout, jumping 55% in the quarter. This fits with Raia Drogasil’s strategy to build out its digital ecosystem, including the 4Bio platform.

The company’s adjusted net income includes 4Bio, its digital health arm. That segment is growing fast but requires heavy upfront investment, which drags on overall profitability.

Why This Matters for Latin America Investors

For anyone living in or invested in Brazil, this report signals where consumer spending is heading. Pharmacy retail is a defensive sector that reflects domestic demand, and an 18.3% revenue jump shows Brazilians are spending on health despite a still-tight economy.

But the profit lag is a caution flag. It suggests that expanding quickly in Brazil’s competitive retail landscape means accepting thinner margins, at least for now.

Analyst Views and Share Price

Despite the modest profit growth, investors cheered the results. Shares rose 5.4% on the news, as earnings per share beat expectations, according to Investing.com transcripts.

The market likely focused on the strong top line and stable core earnings margin as proof that Raia Drogasil’s expansion strategy is working. Over the longer run, higher volume should eventually turn into higher profits as digital efficiencies kick in.

Frequently Asked Questions

Sources: RD Saúde investor relations; Valor Econômico